Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN

05/22/2017 | 04:50pm EST

NEW YORK, May 22, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On May 22, 2017, Amgen disclosed that its osteoporosis medicine Evenity raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by the Company, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine.

On this news, Amgen's share price has fallen as much as $3.42 or 2.20%, during intraday trading on May 22, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amgen-inc--amgn-300461711.html

SOURCE Pomerantz LLP


© PRNewswire 2017
All news about AMGEN INC.
12:43pAMGEN  : SVB Leerink Adjusts Price Target on Amgen to $252 From $245, Maintains ..
MT
09:26aAMGEN  : Tezepelumab Is the First Biologic To Significantly Reduce Exacerbations..
AQ
01:25aPRESS RELEASE  : Heidelberg Pharma Expands Management Team
DJ
02/26AMGEN  : No Water, No Power and Freezing Temperatures for Some Texas Employees
PU
02/26ASTRAZENECA  : Amgen Drug Candidate for Severe Asthma Shows Potential in Late-St..
MT
02/26AMGEN  : AstraZeneca Report Full Positive Phase 3 Tezepelumab Results
DJ
02/26AMGEN  : AstraZeneca-Amgen drug could widen treatment options for severe asthma
RE
02/26AMGEN  : Broad Functional Claim Limitations Raise The Bar For Fulfilling Enablem..
AQ
02/26BEIGENE  : Widens Loss in Q4 2020 as Expenses Balloon; Shares Slide 3%
MT
02/25AMGEN  : Sharpening the Focus on Supplier Diversity and Health Equity
PU
More news